HK1118276A1 - Ethanolamine salt of n-(3-methoxy-5-methylpyrazin-2yl)-2-(4-[1,3,4- oxadiazole-2-yl]phenyl)pyridine-3-sulphonamide - Google Patents

Ethanolamine salt of n-(3-methoxy-5-methylpyrazin-2yl)-2-(4-[1,3,4- oxadiazole-2-yl]phenyl)pyridine-3-sulphonamide

Info

Publication number
HK1118276A1
HK1118276A1 HK08109379.4A HK08109379A HK1118276A1 HK 1118276 A1 HK1118276 A1 HK 1118276A1 HK 08109379 A HK08109379 A HK 08109379A HK 1118276 A1 HK1118276 A1 HK 1118276A1
Authority
HK
Hong Kong
Prior art keywords
methylpyrazin
sulphonamide
pyridine
methoxy
phenyl
Prior art date
Application number
HK08109379.4A
Other languages
English (en)
Inventor
Catherine Good
Phillip John Hogan
Frank Montgomery
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1118276A1 publication Critical patent/HK1118276A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HK08109379.4A 2005-07-19 2008-08-21 Ethanolamine salt of n-(3-methoxy-5-methylpyrazin-2yl)-2-(4-[1,3,4- oxadiazole-2-yl]phenyl)pyridine-3-sulphonamide HK1118276A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0514743.4A GB0514743D0 (en) 2005-07-19 2005-07-19 Salt
PCT/GB2006/002654 WO2007010235A1 (en) 2005-07-19 2006-07-17 Ethanolamine salt of n- (3-methoxy-5-methylpyrazin-2yl) -2- (4- [1 , 3 , 4-0xadiaz0le-2-yl] phenyl) pyridine-3- sulphonamide

Publications (1)

Publication Number Publication Date
HK1118276A1 true HK1118276A1 (en) 2009-02-06

Family

ID=34897419

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08109379.4A HK1118276A1 (en) 2005-07-19 2008-08-21 Ethanolamine salt of n-(3-methoxy-5-methylpyrazin-2yl)-2-(4-[1,3,4- oxadiazole-2-yl]phenyl)pyridine-3-sulphonamide

Country Status (23)

Country Link
US (2) US20080221124A1 (hr)
EP (1) EP1904490B1 (hr)
JP (1) JP5085544B2 (hr)
KR (1) KR20080031042A (hr)
CN (1) CN101223165B (hr)
AT (1) ATE482952T1 (hr)
AU (1) AU2006271420B2 (hr)
CA (1) CA2615596A1 (hr)
CY (1) CY1110942T1 (hr)
DE (1) DE602006017220D1 (hr)
DK (1) DK1904490T3 (hr)
ES (1) ES2351442T3 (hr)
GB (1) GB0514743D0 (hr)
HK (1) HK1118276A1 (hr)
HR (1) HRP20100621T1 (hr)
IL (1) IL188389A0 (hr)
MX (1) MX2008000889A (hr)
NO (1) NO20080053L (hr)
PL (1) PL1904490T3 (hr)
PT (1) PT1904490E (hr)
SI (1) SI1904490T1 (hr)
WO (1) WO2007010235A1 (hr)
ZA (1) ZA200800328B (hr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
GB0914287D0 (en) * 2009-08-14 2009-09-30 Pci Biotech As Compositions
CN102491973A (zh) * 2011-12-15 2012-06-13 南京友杰医药科技有限公司 Zd-4054的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
US20020055457A1 (en) * 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
US20030092757A1 (en) * 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
EP1458715B1 (en) * 2001-12-18 2005-12-07 AstraZeneca AB Novel compounds
GB0219660D0 (en) * 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use

Also Published As

Publication number Publication date
CN101223165A (zh) 2008-07-16
WO2007010235A1 (en) 2007-01-25
AU2006271420A1 (en) 2007-01-25
ES2351442T3 (es) 2011-02-04
JP2009501774A (ja) 2009-01-22
SI1904490T1 (sl) 2010-12-31
AU2006271420B2 (en) 2010-09-23
ZA200800328B (en) 2008-12-31
DK1904490T3 (da) 2010-12-13
EP1904490A1 (en) 2008-04-02
DE602006017220D1 (de) 2010-11-11
WO2007010235A8 (en) 2008-03-13
MX2008000889A (es) 2008-03-18
HRP20100621T1 (hr) 2010-12-31
PL1904490T3 (pl) 2011-02-28
ATE482952T1 (de) 2010-10-15
US20120101109A1 (en) 2012-04-26
JP5085544B2 (ja) 2012-11-28
US20080221124A1 (en) 2008-09-11
CN101223165B (zh) 2011-10-19
CA2615596A1 (en) 2007-01-25
KR20080031042A (ko) 2008-04-07
EP1904490B1 (en) 2010-09-29
CY1110942T1 (el) 2015-06-10
GB0514743D0 (en) 2005-08-24
IL188389A0 (en) 2008-04-13
PT1904490E (pt) 2010-11-18
NO20080053L (no) 2008-04-16

Similar Documents

Publication Publication Date Title
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
EA200800201A1 (ru) Кристаллические формы 4-метил-n-[3-(4-метилимидазол-1-ил)-5-трифторметилфенил]-3-(4-пиридин-3-илпиримидин-2-иламино)бензамида
MX2009006579A (es) 4-{4-[({3-terbutil-1-[3-(hidroximetil]fenil]-1h-pirazol-5-il}carb amoil)-amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida asi como precursores y sales de los mismos para el tratamiento de cancer.
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
RS52169B (en) STABLE LAKVINIMOD PREPARATIONS
ECSP056229A (es) Una composición farmacéutica que comprende formas polimórficas de 3-(4-amino-1-oxo-1.3 dyhidro-isoindol-2-il)-piperidina-2,6-diona para el tratamiento y manejo de cánceres
EA201000888A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и 2-фенилциклогексан-1,3,5-трионы в качестве гербицидов
CL2011003138A1 (es) N-(protegido- n-(3-metoxi-5-metilpirazon-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridino-3-sulfonamida y su proceso de preparacion.
DK1804589T3 (da) Fedtsammensætninger
HRP20090229T1 (hr) Kombinacija koja sadrži n-(3-metoksi-5-metilpirazin-2-il)-2-(4-[1,3,4-oksadijazol-2-il]fenil)piridin-3-sulfonamid i bisfosfonat
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
MX2010003989A (es) Composicion zibotentan que contiene mannitol y/o celulosa microcristalina.
EA201000702A1 (ru) Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы
EA200801413A1 (ru) Гетероциклические сетр ингибиторы
EA200801351A1 (ru) Фунгицидные смеси, которые содержат боскалид и пириметанил
IS7766A (is) N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-[1,3,4-oxadíasól-2-ýl]fenýl)pýridín-3-súlfónamíð sem krabbameinslyf
IL179346A0 (en) 3-(4-(2-dihydroisoxazol-3-ylpyridin-5-yl)phenyl)-5-triazol-1-ylmethyloxazolidin-2-one derivatives as mao inhibitors for the treatment of bacterial infections
EA200900942A1 (ru) Гербицидная композиция
HK1118276A1 (en) Ethanolamine salt of n-(3-methoxy-5-methylpyrazin-2yl)-2-(4-[1,3,4- oxadiazole-2-yl]phenyl)pyridine-3-sulphonamide
WO2003047517A3 (en) Novel-n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-(trifluoromethyl)-1-h-pyrazole-5-carboxamides as factor xa
IL189286A0 (en) Novel cysteine protease inhibitors and their therapeutic applications
UA92592C2 (en) Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic cytotoxic agent such as taxane for the treatment of cancer
UA98676C2 (ru) Композиция зиботентана, содержащая маннит и микрокристаллическую целлюлозу
CL2007002391A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de fibrosis.
UA3387U (uk) Застосування 2-феніл-3-карбетокси-4-диметиламінометил-5-оксибензофурану гідрохлориду (вінборону) як утеролітичного засобу

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140717